Drug Monitoring, Panel 1, Screen, Urine : 39416

QPAN1U or 39416

Prescription Drug Monitoring, Pain Management

Amphetamines, Barbiturates, Benzodiazepines, Marijuana Metabolite, Cocaine Metabolite, Methadone Metabolite, Opiates, Oxycodone, Phencyclidine, and Specimen validity consisting of Creatinine, Oxidant, and pH testing.

Preferred Specimen
30 mL urine

Alternative Specimen
Urine collected in urine collection container

Minimum Volume
7 mL

Transport Container
Clinical drug test transport vial

Room temperature.

Room temperature: 5 days; Refrigerated: 7 days; Frozen: 30 days

Preserved samples

Varies

See Laboratory Report

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative.